Edition:
United States

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

21.96USD
19 Jan 2018
Change (% chg)

$0.14 (+0.64%)
Prev Close
$21.82
Open
$21.78
Day's High
$22.30
Day's Low
$21.25
Volume
104,887
Avg. Vol
215,150
52-wk High
$49.21
52-wk Low
$19.73

Chart for

About

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in... (more)

Overall

Beta: 3.74
Market Cap(Mil.): $635.31
Shares Outstanding(Mil.): 28.93
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 215.97 17.86
EPS (TTM): -- -- --
ROI: -- -7.01 33.11
ROE: -- -27.69 17.05

BRIEF-Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration With Bristol-Myers Squibb

* FIVE PRIME THERAPEUTICS EARNS IND MILESTONE PAYMENT UNDER IMMUNE CHECKPOINT PATHWAYS DISCOVERY COLLABORATION WITH BRISTOL-MYERS SQUIBB AND ANNOUNCES THAT BMS HAS EXTENDED THE RESEARCH TERM OF THIS COLLABORATION FOR A SECOND TIME

Jan 08 2018

BRIEF-Five Prime Therapeutics Submits Investigational New Drug Application For FPA150

* FIVE PRIME THERAPEUTICS SUBMITS INVESTIGATIONAL NEW DRUG APPLICATION FOR NOVEL B7-H4 ANTIBODY FPA150

Jan 03 2018

BRIEF-Five Prime Therapeutics And Zai Lab Announce Exclusive License Agreement

* FIVE PRIME THERAPEUTICS AND ZAI LAB ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR FPA144 ANTI-FGFR2B ANTIBODY IN GREATER CHINA AND GLOBAL STRATEGIC DEVELOPMENT COLLABORATION

Dec 19 2017

BRIEF-Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors

* Bristol-Myers Squibb and Five Prime present phase 1a/1b data evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in patients with advanced solid tumors

Nov 09 2017

BRIEF-Five Prime posts Q3 loss of $1.54 per share

* Five prime announces third quarter 2017 results and provides business update

Nov 06 2017

BRIEF-Five Prime Therapeutics appoints Aron Knickerbocker as CEO

* Five Prime Therapeutics announces appointment of Aron Knickerbocker as CEO effective January 1, 2018

Oct 23 2017

BRIEF-Five Prime to feature two oral data presentations at ESMO congress

* Five Prime to feature two oral data presentations at ESMO 2017 congress Source text for Eikon: Further company coverage:

Aug 29 2017

BRIEF-Five Prime Therapeutics delivered to Inhibrx written notice of termination of agreement

* ‍Pursuant to terms of agreement, termination of agreement will become effective on december 27, 2017 (not 'december 27, 201')​

Aug 28 2017

BRIEF-Five Prime Therapeutics Q2 loss per share $1.58

* Five Prime announces second quarter 2017 results and provides business update

Aug 08 2017

Competitors

  Price Chg
DAIICHI SANKYO COMPANY, LIMITED (4568.T) ¥3,303 +64.00
Novartis AG (NOVN.S) CHF83.38 +0.48
AstraZeneca plc (AZN.L) 5,043.00 +62.50
Eli Lilly and Co (LLY.N) $85.49 -0.33
ArQule, Inc. (ARQL.OQ) $1.73 +0.05

Earnings vs. Estimates